- Home
- LDWY vs CERO Comparison
LDWY vs CERO Comparison
Compare LDWY & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- CERO
- Stock Information
- Founded
- LDWY 1990
- CERO 2017
- Country
- LDWY United States
- CERO United States
- Employees
- LDWY N/A
- CERO N/A
- Industry
- LDWY Advertising
- CERO
- Sector
- LDWY Consumer Discretionary
- CERO
- Exchange
- LDWY Nasdaq
- CERO Nasdaq
- Market Cap
- LDWY 9.2M
- CERO 5.6M
- IPO Year
- LDWY 1991
- CERO N/A
- Fundamental
- Price
- LDWY $5.15
- CERO $5.43
- Analyst Decision
- LDWY
- CERO Strong Buy
- Analyst Count
- LDWY 0
- CERO 2
- Target Price
- LDWY N/A
- CERO $45.00
- AVG Volume (30 Days)
- LDWY 5.5K
- CERO 306.0K
- Earning Date
- LDWY 08-28-2025
- CERO 08-22-2025
- Dividend Yield
- LDWY N/A
- CERO N/A
- EPS Growth
- LDWY N/A
- CERO N/A
- EPS
- LDWY 1.66
- CERO N/A
- Revenue
- LDWY $71,244,000.00
- CERO N/A
- Revenue This Year
- LDWY N/A
- CERO N/A
- Revenue Next Year
- LDWY N/A
- CERO N/A
- P/E Ratio
- LDWY $3.03
- CERO N/A
- Revenue Growth
- LDWY 187.12
- CERO N/A
- 52 Week Low
- LDWY $3.02
- CERO $4.27
- 52 Week High
- LDWY $6.19
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- LDWY 45.96
- CERO 32.53
- Support Level
- LDWY $4.64
- CERO $4.27
- Resistance Level
- LDWY $5.35
- CERO $5.65
- Average True Range (ATR)
- LDWY 0.33
- CERO 0.54
- MACD
- LDWY -0.07
- CERO -0.17
- Stochastic Oscillator
- LDWY 32.90
- CERO 31.12
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.